OncoMatch/Clinical Trials/NCT07283900
Ascorbate in Myelodysplastic Syndrome
Is NCT07283900 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including High-dose ascorbate and Azacitidine for myelodysplastic syndromes.
Treatment: High-dose ascorbate · Azacitidine — This is an open-label, phase II clinical trial with safety run-in evaluating the safety, tolerability, and efficacy of IV HDA in combination with azacitidine for participants with MDS.
Check if I qualifyExtracted eligibility criteria
Cancer type
Myelodysplastic Syndrome
Disease stage
Required: Stage MODERATE HIGH, HIGH, VERY HIGH (Molecular International Prognostic Scoring System (IPSS-M))
Higher-risk MDS per the Molecular International Prognostic Scoring System (IPSS-M) - Moderate High, High, or Very High risk categories.
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: MDS-directed therapy
Exception: ≤ 1 prior cycle of azacitidine, decitabine, or oral decitabine-cedazuridine; or prior use of ESA, luspatercept, or imetelstat. Prior hydroxyurea use is allowed but continuation beyond Cycle 1 requires PI approval.
No prior MDS-directed therapy, except: ≤ 1 prior cycle of azacitidine, decitabine, or oral decitabine-cedazuridine; or prior use of ESA, luspatercept, or imetelstat. Prior hydroxyurea use is allowed but continuation beyond Cycle 1 requires PI approval.
Lab requirements
Kidney function
creatinine clearance >45 ml/min
Liver function
total bilirubin ≤1.5 × uln; alt and ast ≤3 × uln
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Iowa · Iowa City, Iowa
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify